Storia in 4 fonti

What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 g fa

What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)

AbCellera raised $200M; lead program ABCL635 hit new efficacy benchmark for menopausal symptoms. Positive trial data + capital boost fuel 136% YoY momentum and analyst upgrades ($30 targets), signaling strong market confidence in its therapeutic pipeline.

originale

morningstar.com13 h fa

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded…

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Leggi questa versione →

What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)

Confronto fonti

What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded…

Timeline cronologica

AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' - AbCellera Biologics (NASDAQ:ABCL

AbCellera stock surges on ABCL635 menopause Phase 2 trial results

AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment

AbCellera stock surges on ABCL635 menopause Phase 2 trial results

What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants